| Biomarker ID | 380 |
| PMID | 18948370 |
| Year | 2008 |
| Biomarker | Serum PSA + DRE + Methylation Status of RARB |
| Biomarker Basis | Methylation Based |
| Biomolecule | mRNA |
| Source | Expressed Prostatic Secretion |
| Subjects | Humans |
| Regulation | Hypermethylated in Prostate Cancer |
| Odds Ratio/Hazard Ratio/Relative Risk | OR = 2.064 (95% CI: 1.030–6.551) |
| Effect on Pathways | Pathways Include:-Non-small cell lung cancer,Vitamin A and carotenoid metabolism,Nuclear receptor transcription pathway,Nuclear receptors,Small cell lung cancer |
| Experiment | Benign vs. PCA |
| Type of Biomarker | Diagnostic |
| Cohort | Of the 74 specimen cohort, only the 63 that yielded >300 ng total nucleic acid were used for DNA methylation analysis.Out of which 33 had Benign tumors and 30 had PCA. |
| Senstivity | NA |
| Specificity | NA |
| AUC | 0.705 (95% CI: 0.576–0.835) |
| Accuracy | NA |
| Level Of Significance | p<0.06 |
| Method Used | methylation-sensitive TaqMan QPCR |
| Clinical | No |
| Remarks | For Analysis, Serum PSA, plus Digital rectal Exam plus a marker was chosen for analysis and compared to whether they improved performance over analysis done by only Serum PSA + DRE |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | RARB |